EHA 2023 | Disease characteristics impacting treatment decisions in CLL
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines disease characteristics that impact treatment decisions in chronic lymphocytic leukemia (CLL), commenting on the impact of mutations including TP53, del(17p), and IgHV, and discussing how targeted therapies have changed the treatment landscape of CLL. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miragen Therapeutics Inc, Novartis, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, Xencor; Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair, CLL).
